Related Experiment Video
Updated: Aug 24, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Starting highly active antiretroviral therapy: why, when and response to HAART
Amanda Mocroft1, Jens D Lundgren
1Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK. a.mocroft@pcps.ucl.ac.uk
Abstract:
Highly active antiretroviral therapy (HAART) has dramatically improved the prognosis of patients with HIV, although it remains unclear as to the best time to start treatment to reduce the risk of clinical progression. The initial virological response to HAART, by reducing viral load to below the limit of detection, is essential for reducing the risk of drug resistance, which in the longer term may lead to a deterioration in immune function and an increased risk of clinical disease progression. There has been a switch to more conservative therapy recently, given concerns about toxicities and the difficulties of adhering to a complicated regimen long term.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Antiviral Nucleoside Inhibitors
Size and Structure of Viral Genomes
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Inhibitors of Virion Maturation and Assembly

